Sign In
Buy PYPD
$4.29
-0.0800 (-1.83%)
At Close: Jul 31, 2026
PolyPid to Participate in Citizens JMP Life Sciences Conference
07:00am, Wednesday, 01'st May 2024
PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today anno
Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
07:00am, Wednesday, 24'th Apr 2024
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today a
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
07:00am, Wednesday, 28'th Feb 2024
PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today a
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Monday, 19'th Feb 2024
PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript
11:13am, Wednesday, 14'th Feb 2024
PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
07:00am, Wednesday, 14'th Feb 2024
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
07:00am, Monday, 12'th Feb 2024
Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Rec
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
07:00am, Wednesday, 31'st Jan 2024
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today an
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
04:32pm, Thursday, 04'th Jan 2024
PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today an
PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript
01:08am, Sunday, 12'th Nov 2023
PolyPid Ltd. (NASDAQ:PYPD ) Q3 2023 Earnings Conference Call November 11, 2023 8:00 AM ET Company Participants Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Off
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
07:00am, Wednesday, 08'th Nov 2023
Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
07:00am, Tuesday, 07'th Nov 2023
Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appo
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023
07:00am, Wednesday, 01'st Nov 2023
PETACH TIKVA, Israel, Nov. 01, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today an
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
07:00am, Wednesday, 11'th Oct 2023
PETACH TIKVA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today anno
